Reprogram gastric tissue to functional insulin-secreting cells

将胃组织重新编程为功能性胰岛素分泌细胞

基本信息

  • 批准号:
    9221317
  • 负责人:
  • 金额:
    $ 46.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-01 至 2021-02-28
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): One major goal of regenerative medicine is to produce insulin secreting β-cells for transplantation therapy to treat Type 1 diabetes (T1D). Differentiation of embryonic stem cells is a powerful technology to generate functional insulin+ cells. However, teratoma formation is a serious concern with this approach. Alternatively, adult tissues could be converted into insulin+ cells in a process termed reprogramming. Reprogramming adult cells carries little risk for teratoma, but the reprogramming efficiency tends to be low and the resulting insulin+ cells have limited functionality. There is a critical ned to define the best tissue source and reprogramming method for this approach. My laboratory pioneered a reprogramming method based on a cocktail of defined genetic factors (Ngn3, Pdx1, Mafa, referred to as NPM factors). NPM factors are sufficient to convert pancreatic acinar cells to stable and functional insulin+ cells in animal models. In a comprehensive screen of adult tissues, we discovered that cells residing in the adult gastric mucosa also respond rapidly to NPM factors and generate functional insulin+ cells. Significantly, gastric insulin+ cells become glucose responsive faster than acinar-derived insulin+ cells. Thus, gastric tissue is a highly promising adult tissue source to produce functional insulin+ cells. Importantly, human gastric cells can be cultured and propagated as organoids in large numbers from cadaveric sources. Delivery of NPM factors led to formation of c-peptide+ cells in the human organoids, raising the exciting possibility of generating functional human insulin+ cells with this approach. One major aim of the proposal is to gain deeper understanding of the reprogramming process and the resulting gastric insulin+ cells. Specifically, we will determine the molecular and functional similarity of the induced gastric insulin+ cells with native islet beta-cells. We will investigate stability of the induced cells and test the hypothesis that islet structure formation will lead to heir long-term stability. We will also define the individual function of NPM factors in the reprogramming process. The second major aim of the proposal is to develop methods for efficient induction of functional insulin+ cells from human gastric tissues with combined treatment of genetic factors and signaling pathway modulators. Together, these studies will provide the necessary foundation for developing a novel technology to produce functional human insulin+ cells for therapeutic transplantation.
 描述(申请人提供):再生医学的一个主要目标是产生分泌胰岛素的β细胞,用于移植治疗1型糖尿病(T1D)。胚胎干细胞的分化是一项产生功能性胰岛素+细胞的强大技术。然而,畸胎瘤的形成是这种方法的一个严重问题。或者,成人组织可以在一种称为重编程的过程中转化为胰岛素+细胞。对成人细胞重新编程对畸胎瘤的风险很小,但重新编程的效率往往很低,由此产生的胰岛素+细胞的功能有限。对于这种方法,有一个关键的NED来确定最佳的组织来源和重新编程的方法。我的实验室开创了一种基于已定义遗传因子(Ngn3、Pdx1、Mafa,称为NPM因子)鸡尾酒的重新编程方法。在动物模型中,NPM因子足以将胰腺腺泡细胞转化为稳定和功能正常的胰岛素+细胞。在对成人组织的全面筛查中,我们发现驻留在成人胃粘膜中的细胞也对NPM因子快速反应,并产生功能性胰岛素+细胞。值得注意的是,胃胰岛素+细胞比腺泡来源的胰岛素+细胞对葡萄糖的反应更快。因此,胃组织是一个非常有希望的成人组织来源,以产生功能性的胰岛素+细胞。重要的是,人的胃细胞可以从身体来源大量培养和繁殖为类器官。NPM因子的传递导致了C-肽+细胞在人的类器官中的形成,增加了用这种方法产生功能性人胰岛素+细胞的令人兴奋的可能性。该提案的一个主要目的是更深入地了解重新编程过程和由此产生的胃胰岛素+细胞。具体地说,我们将确定诱导的胃胰岛素+细胞与天然胰岛β细胞在分子和功能上的相似性。我们将研究诱导细胞的稳定性,并验证胰岛结构形成将导致传代长期稳定的假设。我们还将确定NPM因素在重新编制程序过程中的单独作用。该提案的第二个主要目标是开发有效地从人胃组织中诱导具有功能的胰岛素+细胞的方法,并结合遗传因素和信号通路调节剂进行治疗。总之,这些研究将为开发一种新的技术来生产用于治疗性移植的功能性人类胰岛素+细胞提供必要的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Qiao Joe Zhou其他文献

Qiao Joe Zhou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Qiao Joe Zhou', 18)}}的其他基金

Engineering islet-like organoids from gastric stem cells for T1D cell replacement therapy
从胃干细胞中改造胰岛样类器官,用于 T1D 细胞替代疗法
  • 批准号:
    10704110
  • 财政年份:
    2022
  • 资助金额:
    $ 46.61万
  • 项目类别:
Derivation of pancreatic islet-like organoids from human gastric stem cells
从人胃干细胞中衍生胰岛样类器官
  • 批准号:
    10502451
  • 财政年份:
    2022
  • 资助金额:
    $ 46.61万
  • 项目类别:
Derivation of pancreatic islet-like organoids from human gastric stem cells
从人胃干细胞中衍生胰岛样类器官
  • 批准号:
    10689788
  • 财政年份:
    2022
  • 资助金额:
    $ 46.61万
  • 项目类别:
Engineering islet-like organoids from gastric stem cells for T1D cell replacement therapy
从胃干细胞中改造胰岛样类器官,用于 T1D 细胞替代疗法
  • 批准号:
    10512923
  • 财政年份:
    2022
  • 资助金额:
    $ 46.61万
  • 项目类别:
Investigating a master regulator of large intestine stem cells
研究大肠干细胞的主调节因子
  • 批准号:
    10458677
  • 财政年份:
    2021
  • 资助金额:
    $ 46.61万
  • 项目类别:
Investigating a master regulator of large intestine stem cells
研究大肠干细胞的主调节因子
  • 批准号:
    10298777
  • 财政年份:
    2021
  • 资助金额:
    $ 46.61万
  • 项目类别:
Investigating a master regulator of large intestine stem cells
研究大肠干细胞的主调节因子
  • 批准号:
    10671584
  • 财政年份:
    2021
  • 资助金额:
    $ 46.61万
  • 项目类别:
Generating novel sources of functional human insulin-secreting cells for T1D modeling
为 T1D 建模生成功能性人胰岛素分泌细胞的新来源
  • 批准号:
    9459621
  • 财政年份:
    2017
  • 资助金额:
    $ 46.61万
  • 项目类别:
Generating novel sources of functional human insulin-secreting cells for T1D modeling
为 T1D 建模生成功能性人胰岛素分泌细胞的新来源
  • 批准号:
    9849886
  • 财政年份:
    2017
  • 资助金额:
    $ 46.61万
  • 项目类别:
Reprogram gastric tissue to functional insulin-secreting cells
将胃组织重新编程为功能性胰岛素分泌细胞
  • 批准号:
    9916632
  • 财政年份:
    2016
  • 资助金额:
    $ 46.61万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.61万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了